Come up with a name for your new list and we'll add to it:
Pieris raised a round of funding on February 08, 2012. Investors include
Bundesministerium fur Bildung und Forschung.
Pieris is an independent, clinical-staged biotechnology company advancing its proprietary Anticalin technology to create differentiated drugs that are safer and more effective than conventional approa…